COMPASS Pathways

COMPASS Pathways is a subsidiary of ATAI that aims to develop psilocybin for treatment-resistant depression. It (will soon) go public as the largest psychedelics IPO to date.


“COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first programme is researching how psilocybin therapy could help people with treatment-resistant depression.”

COMPASS has received a FDA breakthrough therapy designation which means that the development of psilocybin-assisted therapy is advancing at an accelerated pace. Currently they are doing a Phase IIb study with 216 patients in Europe and North America.

The company has also invested in Delix Therapeutics, “a drug discovery and development company researching novel small molecules for use in CNS indications.”

The company plans to offer their COMP360 therapy in 2025 (or later).

Key Staff

  • Ekaterina Malilevskaia – CIO & Co-founder
  • George Goldsmith – CEO & Co-founder
  • Lars Christian Wilde – President, CBO & Co-founder
  • Robin Carhart-Harris – Scientific Advisory Board
  • David Nutt – Scientific Advisory Board


The company has raised $80 million for its phase III trials. Previously it has raised $31 million for the phase II trials. ATAI is the largest investor in COMPASS.

As of September 2020, it’s listed on the Nasdaq under the ticker CMPS and has raised over $100 million at a $600 million valuation (which jumped to $1.1 billion within days). This is in addition to the previous $116 million (estimated) that it has raised before September.


Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account